Last updated: May 24, 2026
What is STIMATE (desmopressin acetate) and what are the latest clinical-trials and regulatory signals?
STIMATE is a U.S. marketed intranasal formulation of desmopressin acetate used for indications including central diabetes insipidus (CDI) and nocturnal enuresis (indication set depends on the specific label and age group).
Clinical-trials activity (practical lens for investors)
- For established generics and reference products built on a known API like desmopressin, “clinical trial updates” typically come from:
- label-expansion studies,
- bioequivalence/PK bridging work for reformulations or manufacturing changes,
- post-marketing commitments.
- For STIMATE specifically, a complete, current “latest trials” update requires a current record set across ClinicalTrials.gov and FDA postmarketing documentation. No such record set is available in the provided information.
Because no verifiable, source-backed trial identifiers, dates, recruitment status, endpoints, or study cohorts are provided, a complete “latest clinical trials update” cannot be produced without risking factual errors.
What is the US FDA status of STIMATE (NDA/BLA, Orange Book listing, and therapeutic coverage)?
STIMATE’s FDA status and enforceable exclusivities in the U.S. are determined by:
- the approved application (NDA number),
- the Orange Book patent listings (drug substance, drug product, and method-of-use),
- whether exclusivity is from 505(j) paragraph-eligible approvals, new clinical investigations, or other statutory exclusivity frameworks,
- any orphan designation (if applicable), and
- the status of pending/issued patent infringement cases tied to ANDA filings.
No Orange Book listing details, NDA number, listed patents, or exclusivity end dates for STIMATE are included in the input. Without those, any claim about Orange Book status, patent counts, or exclusivity end dates would be speculative.
How many patents protect STIMATE in the US, and what patent types dominate (drug substance, drug product, method-of-use)?
A robust patent-estate map requires, at minimum:
- the set of Orange Book-listed patents for STIMATE,
- their US publication numbers, grant numbers, assignee/patentee, and expiration dates,
- classification into:
- composition-of-matter (drug substance),
- formulation/composition (drug product),
- method-of-use (therapeutic regimen),
- and any process/manufacturing patents relevant to ANDA design-around.
None of those patent identifiers are provided. A quantified “how many patents” answer cannot be produced from the supplied context without introducing inaccuracies.
When does STIMATE lose exclusivity in the US (patent expiration and exclusivity windows)?
An accurate exclusivity timeline for STIMATE must be derived from:
- each listed patent’s expiration (and any granted PTA),
- each statutory exclusivity start/end (5-year, 3-year, 7-year orphan, pediatric exclusivity, etc.),
- and any Hatch-Waxman carve-outs triggered by litigation or “carve-out” settlements.
No expiration dates or exclusivity types for STIMATE are provided, so a timeline cannot be completed.
Which companies are challenging STIMATE with ANDAs (Paragraph IV) and how do those filings change generic launch risk?
Paragraph IV challenge risk analysis depends on:
- the ANDA filer name(s),
- date(s) of certification (Para IV),
- the referenced listed patents,
- the resulting litigation case number(s),
- and whether an early settlement triggers a “first generic” launch date.
No ANDA filer or Para IV litigation information is provided, so the market risk profile cannot be stated.
What generic and authorized generic entry risks exist for STIMATE?
For a legacy intranasal desmopressin product, generic entry risk typically hinges on:
- formulation/pump-spray or spray-system constraints,
- preservative system constraints and particle/microdelivery profile,
- any method-of-use patents (nocturnal enuresis dosing/intervals, age-specific regimens),
- and any device-related constraints if the product uses a distinctive delivery system.
Without STIMATE-specific patent and formulation details, any “generic entry risk” score would be nonfactual.
How does STIMATE compare with other desmopressin nasal products on patent and commercialization dynamics?
A comparison requires:
- competing products in the same therapeutic area (same route: intranasal),
- their Orange Book patent sets and exclusivity status,
- their approved strengths/dosing and label limitations,
- and their current market positions.
No competitor product list, patent estates, or revenue/volume metrics are provided for STIMATE or its peers, so a comparative analysis cannot be executed.
What formulations and delivery systems are protected for STIMATE (spray, buffer, preservatives, dose accuracy)?
Formulation IP coverage requires:
- claim sets for drug product patents (excipients, buffer concentration, preservative system, particle size or droplet properties, spray characteristics),
- ANDA suitability for “same as” versus “different formulation” design-around.
No formulation patent data for STIMATE is provided.
What patent litigation affects STIMATE (case status, settlements, and launch triggers)?
Litigation analysis needs:
- case caption, court, docket number,
- patents-in-suit,
- procedural milestones (complaint, answer, Markman, summary judgment),
- settlement dates and terms that set launch/at-risk dates.
No litigation identifiers or outcomes are provided.
What biosimilar risk applies to STIMATE?
STIMATE is small-molecule desmopressin, not a biologic. Biosimilar frameworks do not apply. A biosimilar section is therefore not applicable as an exclusivity-risk driver.
What is the market size for desmopressin intranasal products, and where does STIMATE sit in the competitive landscape?
A market projection requires at least one of:
- historical U.S. prescription trends by NDC/label,
- IQVIA or similar datapoints,
- payer and channel mix,
- price and gross-to-net dynamics,
- and competitor share by strength and indication.
No market metrics or STIMATE-specific unit/revenue data are provided.
How to project STIMATE revenue over the next 5–7 years (drivers, downside, and scenarios)
A defensible projection needs:
- baseline U.S. revenue and unit trend,
- expected competitive entry dates (generics/authorized generics),
- expected price erosion,
- and whether any label expansions or supply events are expected.
No baseline revenue, units, or entry timing are provided; a projection cannot be produced.
Key data table: STIMATE dossier elements needed to run an IP and commercial forecast
| Category |
Data required for a correct forecast |
Status in provided input |
| FDA application |
NDA number, approval date, label/strengths |
Not provided |
| Orange Book |
Listed patent numbers, assignees, expiration, exclusivity flags |
Not provided |
| Exclusivity |
5/3/7-year and pediatric/orphan/patent-term-extension schedule |
Not provided |
| Clinical trials |
ClinicalTrials.gov IDs, status, endpoints, enrollment |
Not provided |
| Para IV |
ANDA filer, patents challenged, case number, settlement/launch triggers |
Not provided |
| Market |
U.S. prescriptions, NDC units, WAC/ASP history, payer mix |
Not provided |
Key Takeaways
- STIMATE is an established intranasal desmopressin product, but a source-backed “clinical trials update,” “market analysis,” and “5–7 year projections” cannot be produced from the information provided.
- A correct patent and exclusivity outlook requires Orange Book patent listings and expiration/exclusivity dates.
- A correct generic entry risk analysis requires Paragraph IV/ANDA litigation data and/or settlement launch triggers.
- A correct market forecast requires baseline unit and revenue history plus expected competitive entry timing.
FAQs
- What Orange Book patents typically cover intranasal desmopressin products and how are they categorized (drug product vs method-of-use)?
- How do Paragraph IV certifications and litigation affect a first generic launch for established intranasal generics?
- What endpoints and endpoints timing are most common in desmopressin nasal PK/bridging studies?
- How do formulation and delivery-system variables (preservatives, buffers, spray characteristics) drive design-around risk in ANDAs?
- For small-molecule nasal drugs like desmopressin, what are the main exclusivity levers besides listed patents?
References
No sources were provided in the prompt.
